DATE: February 7, 2017
TIME: 10:00am PT, 1:00pm ET

In this webinar, Jeffrey G. Reid, PhD, Executive Director and Head of Genome Informatics at Regeneron Pharmaceuticals, will share how the Regeneron Genetics Center (RGC) has built one of the world’s most comprehensive genetics databases, pairing the sequenced exomes and de-identified electronic health records of more than 100,000 people to date, with plans to ultimately sequence more than 250,000 people.  

Described as the largest clinical sequencing undertaking in North America, the RGC collaborates with 30 institutions to marry healthcare provider and academic expertise with translational follow up, in essence making data actionable. By analyzing genomic and phenotypic data and making associations between genes and disease, the goal of the RGC collaboration is to make discoveries that inform and speed the drug development process. Ultimately, the hope is to improve patient healthcare outcomes through the development of new therapeutics for a broad range of serious medical conditions. 

Regeneron selected DNAnexus to provide the cloud-based bioinformatics platform that enables various RCG research partnerships through the sharing and management of large-scale sequencing data and genomic tools. On February 7th, hear from one of the leading genetic experts discuss RGC’s integrated approach across genetic trait architectures and phenotypes, the underlying cloud infrastructure that makes possible the multi-institution collaboration, and key lessons learned from RGC’s pioneering genomic sequencing study. 

Learning Objectives:

• Why Regeneron is investing in human genetics
• How the marriage between genotypes and phenotypes supports target drug discovery & validation